Erratum: T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells (Cancer Cell (2016) 30(3) (377–390)(S1535610816303890)(10.1016/j.ccell.2016.08.004));T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells

Cancer Cell

Volumn 30, Issue 3, 2016, Pages 377-390

  Marigo, Ilaria ^a   Zilio, Serena ^b   Desantis, Giacomo ^a   Mlecnik, Bernhard ^c,d,e   Agnellini, Andrielly H R ^b   Ugel, Stefano ^f   Sasso, Maria Stella ^b   Qualls, Joseph E ^g   Kratochvill, Franz ^g   Zanovello, Paola ^a,b   Molon, Barbara ^a   Ries, Carola H ^h   Runza, Valeria ^h   Hoves, Sabine ^h   Bilocq, Amélie M ^c,d,e   Bindea, Gabriela ^c,d,e   Mazza, Emilia M C ⁱ   Bicciato, Silvio ⁱ   Galon, Jérôme ^c,d,e   Murray, Peter J ^g   Bronte, Vincenzo ^f   more..

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c INSERM   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e CENTRE DE RECHERCHE DES CORDELIERS   (France)

^f UNIVERSITY HOSPITAL OF VERONA   (Italy)

^g ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^h ROCHE DIAGNOSTICS GMBH   (Germany)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; COLONY STIMULATING FACTOR 1 RECEPTOR; CYTOKINE RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ARGINASE; NOS2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE EXPRESSION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN INDUCTION; T LYMPHOCYTE; THERAPY EFFECT; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR REJECTION; TUMOR VOLUME; WILD TYPE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD40; ARGINASE; CD40 LIGAND; CELL LINE, TUMOR; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; NITRIC OXIDE SYNTHASE TYPE II; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84995615046     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.09.009     Document Type: Erratum

References (53)

1. Aldridge, J.R. Jr., Moseley, C.E., Boltz, D.A., Negovetich, N.J., Reynolds, C., Franks, J., Brown, S.A., Doherty, P.C., Webster, R.G., Thomas, P.G., TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc. Natl. Acad. Sci. USA 106 (2009), 5306–5311.
2. Arina, A., Bronte, V., Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. Curr. Opin. Immunol. 33 (2015), 120–125.
3. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., Huhn, R.D., Song, W., Li, D., Sharp, L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331 (2011), 1612–1616.
4. Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., Fridman, W.H., Pages, F., Trajanoski, Z., Galon, J., ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics 25 (2009), 1091–1093.
5. Bindea, G., Galon, J., Mlecnik, B., CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 29 (2013), 661–663.
6. Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A.C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39 (2013), 782–795.
7. Bosschaerts, T., Guilliams, M., Stijlemans, B., Morias, Y., Engel, D., Tacke, F., Herin, M., De Baetselier, P., Beschin, A., Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling. PLoS Pathog., 6, 2010, e1001045.
8. Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5 (2005), 641–654.
9. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
10. Chong, S.Z., Wong, K.L., Lin, G., Yang, C.M., Wong, S.C., Angeli, V., Macary, P.A., Kemeny, D.M., Human CD8(+) T cells drive Th1 responses through the differentiation of TNF/iNOS-producing dendritic cells. Eur. J. Immunol. 41 (2011), 1639–1651.
11. Colegio, O.R., Chu, N., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., Cyrus, N., Borowski, C.E., Eisenbarth, S.C., Phillips, G.M., et al. Functional polarization of tumor-associated macrophages by tumor-derived lactic acid. Nature 513 (2014), 559–563.
12. Conde, P., Rodriguez, M., van der Touw, W., Jimenez, A., Burns, M., Miller, J., Brahmachary, M., Chen, H.M., Boros, P., Rausell-Palamos, F., et al. DC-SIGN(+) macrophages control the induction of transplantation tolerance. Immunity 42 (2015), 1143–1158.
13. Corzo, C.A., Condamine, T., Lu, L., Cotter, M.J., Youn, J.I., Cheng, P., Cho, H.I., Celis, E., Quiceno, D.G., Padhya, T., et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207 (2010), 2439–2453.
14. Duque-Correa, M.A., Kuhl, A.A., Rodriguez, P.C., Zedler, U., Schommer-Leitner, S., Rao, M., Weiner, J. 3rd, Hurwitz, R., Qualls, J.E., Kosmiadi, G.A., et al. Macrophage arginase-1 controls bacterial growth and pathology in hypoxic tuberculosis granulomas. Proc. Natl. Acad. Sci. USA 111 (2014), E4024–E4032.
15. El Kasmi, K.C., Qualls, J.E., Pesce, J.T., Smith, A.M., Thompson, R.W., Henao-Tamayo, M., Basaraba, R.J., Konig, T., Schleicher, U., Koo, M.S., et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat. Immunol. 9 (2008), 1399–1406.
16. Engels, B., Engelhard, V.H., Sidney, J., Sette, A., Binder, D.C., Liu, R.B., Kranz, D.M., Meredith, S.C., Rowley, D.A., Schreiber, H., Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell 23 (2013), 516–526.
17. Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., Pamer, E.G., Li, M.O., The cellular and molecular origin of tumor-associated macrophages. Science 344 (2014), 921–925.
18. + T cells to execute immunologic helper functions. Blood 122 (2013), 405–412.
19. Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12 (2012), 253–268.
20. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
21. Gautier, E.L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow, A., Elpek, K.G., Gordonov, S., et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13 (2012), 1118–1128.
22. Ginhoux, F., Schultze, J.L., Murray, P.J., Ochando, J., Biswas, S.K., New insights into the multidimensional concept of macrophage ontogeny, activation and function. Nat. Immunol. 17 (2015), 34–40.
23. Glynn, S.A., Boersma, B.J., Dorsey, T.H., Yi, M., Yfantis, H.G., Ridnour, L.A., Martin, D.N., Switzer, C.H., Hudson, R.S., Wink, D.A., et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J. Clin. Invest. 120 (2010), 3843–3854.
24. Gommerman, J.L., Summers deLuca, L., LTbetaR and CD40: working together in dendritic cells to optimize immune responses. Immunol. Rev. 244 (2011), 85–98.
25. Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
26. Haverkamp, J.M., Crist, S.A., Elzey, B.D., Cimen, C., Ratliff, T.L., In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur. J. Immunol. 41 (2011), 749–759.
27. Jana, M., Liu, X., Koka, S., Ghosh, S., Petro, T.M., Pahan, K., Ligation of CD40 stimulates the induction of nitric-oxide synthase in microglial cells. J. Biol. Chem. 276 (2001), 44527–44533.
28. Klug, F., Prakash, H., Huber, P.E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R.H., Timke, C., Umansky, L., et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24 (2013), 589–602.
29. Korrer, M.J., Routes, J.M., Possible role of arginase-1 in concomitant tumor immunity. PLoS One, 9, 2014, e91370.
30. Kratochvill, F., Neale, G., Haverkamp, J.M., Van de Velde, L.A., Smith, A.M., Kawauchi, D., McEvoy, J., Roussel, M.F., Dyer, M.A., Qualls, J.E., Murray, P.J., Tnf counterbalances the emergence of M2 tumor macrophages. Cell Rep. 12 (2015), 1902–1914.
31. Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Lower, M., Diekmann, J., Boegel, S., Schrors, B., Vascotto, F., Castle, J.C., et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520 (2015), 692–696.
32. + T cells in human melanoma. Nat. Med. 21 (2015), 81–85.
33. Lowes, M.A., Chamian, F., Abello, M.V., Fuentes-Duculan, J., Lin, S.L., Nussbaum, R., Novitskaya, I., Carbonaro, H., Cardinale, I., Kikuchi, T., et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc. Natl. Acad. Sci. USA 102 (2005), 19057–19062.
34. Marigo, I., Bosio, E., Solito, S., Mesa, C., Fernandez, A., Dolcetti, L., Ugel, S., Sonda, N., Bicciato, S., Falisi, E., et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32 (2010), 790–802.
35. Miller, J.C., Brown, B.D., Shay, T., Gautier, E.L., Jojic, V., Cohain, A., Pandey, G., Leboeuf, M., Elpek, K.G., Helft, J., et al. Deciphering the transcriptional network of the dendritic cell lineage. Nat. Immunol. 13 (2012), 888–899.
36. Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.H., Pages, F., Galon, J., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 29 (2011), 610–618.
37. Mok, S., Koya, R.C., Tsui, C., Xu, J., Robert, L., Wu, L., Graeber, T.G., West, B.L., Bollag, G., Ribas, A., Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 74 (2014), 153–161.
38. Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stange, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70 (2010), 5728–5739.
39. Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61.
40. Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D., Immune modulation in cancer with antibodies. Annu. Rev. Med. 65 (2014), 185–202.
41. Pesce, J.T., Ramalingam, T.R., Mentink-Kane, M.M., Wilson, M.S., El Kasmi, K.C., Smith, A.M., Thompson, R.W., Cheever, A.W., Murray, P.J., Wynn, T.A., Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog., 5, 2009, e1000371.
42. Restifo, N.P., Dudley, M.E., Rosenberg, S.A., Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12 (2012), 269–281.
43. Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L.P., Feuerhake, F., Klaman, I., et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 25 (2014), 846–859.
44. Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19 (2013), 747–752.
45. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
46. Serbina, N.V., Salazar-Mather, T.P., Biron, C.A., Kuziel, W.A., Pamer, E.G., TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 19 (2003), 59–70.
47. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
48. Ugel, S., Scarselli, E., Iezzi, M., Mennuni, C., Pannellini, T., Calvaruso, F., Cipriani, B., De Palma, R., Ricci-Vitiani, L., Peranzoni, E., et al. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood 115 (2010), 1374–1384.
49. Ugel, S., Peranzoni, E., Desantis, G., Chioda, M., Walter, S., Weinschenk, T., Ochando, J.C., Cabrelle, A., Mandruzzato, S., Bronte, V., Immune tolerance to tumor antigens occurs in a specialized environment of the spleen. Cell Rep. 2 (2012), 628–639.
50. Ugel, S., De Sanctis, F., Mandruzzato, S., Bronte, V., Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125 (2015), 3365–3376.
51. Vicetti Miguel, R.D., Cherpes, T.L., Watson, L.J., McKenna, K.C., CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination. J. Immunol. 185 (2010), 6706–6718.
52. Weiss, J.M., Ridnour, L.A., Back, T., Hussain, S.P., He, P., Maciag, A.E., Keefer, L.K., Murphy, W.J., Harris, C.C., Wink, D.A., Wiltrout, R.H., Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med. 207 (2010), 2455–2467.
53. Zhu, Z., Singh, V., Watkins, S.K., Bronte, V., Shoe, J.L., Feigenbaum, L., Hurwitz, A.A., High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res. 73 (2013), 595–604.